Integrated BioPharma Inc (INBP) reported QQ1 2025 revenue of $13.617 million, a year-over-year decline of 45.5% from $24.998 million in QQ1 2024, reflecting a difficult base effect in a small-mcale nutraceuticals-focused franchise. Despite the revenue contraction, the company posted a resilient gross profit of $1.371 million and an EBITDA of $0.81 million, with operating income of $0.49 million and a net income of $0.259 million for the quarter. The quarterly results translate to a gross margin of ~10.07% and an operating margin of ~3.60%, with a net margin of ~1.90%. Cash flow was positive, with cash provided by operations of $0.657 million and free cash flow of $0.601 million, ending the period with roughly $2.271 million in cash and a net cash position of about $0.713 million after accounting for debt.